The Oxford Covid-19 Vaccine Production - A Year in the Fast Lane

Overview

The Clinical Biomanufacturing Facility (CBF) at the University of Oxford (UK) produced the first clinical batches of the ChAdOx1 nCoV-19 vaccine against SARS-coV-2 in April 2020. In collaboration with our industrial partner AstraZeneca we have moved rapidly to get the vaccine into phase III clinical trials across the globe, and interim analysis has shown good safety and efficacy, leading to its licensure in the UK and around the world.

We developed and optimised a route to scaled up manufacture in order to produce millions of doses in the hope that it (in conjunction with other vaccines) will deliver an effective route to end the current pandemic. I will present the efforts that underpinned this highly rapid development of a vaccine against a previously unknown pathogen, the lessons that we have learnt, as well as the results generated from our early phase trials.